YEE PINH JEREMY
Non-Executive Non-Independent Director
Board role from 3 April 2026; former Executive Director and CEO during FY2025The business, the people and the ownership behind Clearbridge.
Business overview
Clearbridge Health is a healthcare group with operations across Asia. Its business includes medical centres and clinics, supported by other healthcare-related business units serving demand for medical services in the region.
Listed security
Board & management
The report-date Board has four directors. Two executive officers are listed. Former Chairman ChenJohnson is separately identified; he ceased as a director on27February2026.
YeePinhJeremy ceased as CEO and became a non-executive non-independent director on3April2026. The report states that the CEO vacancy is under Board review, while existing key management oversees interim operations. No separate Chairman position had been created following ChenJohnson’s departure.
Non-Executive Non-Independent Director
Board role from 3 April 2026; former Executive Director and CEO during FY2025Lead Independent Director
Current Board; Remuneration Committee Chairman; Nominating/Audit Committee MemberIndependent Director
Current Board; Audit Committee Chairman; Remuneration Committee MemberIndependent Director
Current Board; Nominating Committee Chairman; Audit/Remuneration Committee MemberNon-Executive Non-Independent Chairman
Former Board Chairman during FY2025; ceased as Director on27February2026Chief Business Officer
Executive Officers; strategic planning, business monitoring and subsidiary operations in Asia PacificFinancial Controller
Executive Officers; Group financial strategy/management, tax and regulatory complianceRoles listed in ANNUAL REPORT 2025; current appointments are not independently verified.
Holdings
Four substantial holders direct/deemed and20registered/depository holders retained as12March2026; Bonvestsdeemed607,862,467 represents100%heldCoop subsidiary, notextraordinaryshares beyondCoopdirectholding.
Top20nominees do not implybeneficialownership. PrintedregistercapitalS$125,666,971.7526 and4,295,820,825fullshares are laterthan31December2025BS, dates/units retained separately.
OriginalTop20subtotal65.99% differs from direct2,835,627,523/4,295,820,825 percentage66.01%; sourcefigurekeptwithqualification; exactsumofprintedindividualpercentages independentlychecked.
Direct interest: 234,755,361 shares (5.46%); deemed interest: – shares (–%).
Substantial shareholders as recorded in the Register of Substantial ShareholdersDirect interest: 244,346,153 shares (5.69%); deemed interest: – shares (–%).
Substantial shareholders as recorded in the Register of Substantial ShareholdersDirect interest: 607,862,467 shares (14.15%); deemed interest: – shares (–%).
Substantial shareholders as recorded in the Register of Substantial ShareholdersDirect interest: – shares (–%); deemed interest: 607,862,467 shares (14.15%).
Substantial shareholders as recorded in the Register of Substantial Shareholders4,295,820,825 ordinary shares; nil treasury shares; nil subsidiary holdings; one vote per share; issued and paid-up share capital S$125,666,971.7526
Shareholder register as at12March2026; separate from31December2025financialbalance date65.99%Total interest
68.92%
Shareholder register as at12March2026; separate from31December2025financialbalance dateTotal interests include direct and deemed holdings and may overlap across holders. These percentages should not be added together.
Registered holdings, including nominees and depositories; these do not establish ultimate beneficial ownership. As reported at 2026-03-12 · PDF p. 186
| Registered holder | Interest | Shares / units | Source |
|---|---|---|---|
| COOP INTERNATIONAL PTE LTD | 607,862,467 shares; 14.15%. | PDF p. 1862026-03-12 | |
| DBS NOMINEES PTE LTD | 423,779,871 shares; 9.86%. | PDF p. 1862026-03-12 | |
| UOB KAY HIAN PTE LTD | 261,036,600 shares; 6.08%. | PDF p. 1862026-03-12 | |
| PHILLIP SECURITIES PTE LTD | 185,230,824 shares; 4.31%. | PDF p. 1862026-03-12 | |
| HSBC (SINGAPORE) NOMINEES PTE LTD | 166,832,500 shares; 3.88%. | PDF p. 1862026-03-12 | |
| CITIBANK NOMINEES SINGAPORE PTE LTD | 166,226,862 shares; 3.87%. | PDF p. 1862026-03-12 | |
| LEE JINTAO | 100,000,000 shares; 2.33%. | PDF p. 1862026-03-12 | |
| MAYBANK SECURITIES PTE. LTD. | 95,004,000 shares; 2.21%. | PDF p. 1862026-03-12 | |
| LEE MOH MING | 93,269,601 shares; 2.17%. | PDF p. 1862026-03-12 | |
| CHNG KIAT LENG | 86,064,340 shares; 2.00%. | PDF p. 1862026-03-12 | |
| RAMESH S/O PRITAMDAS CHANDIRAMANI | 85,000,000 shares; 1.98%. | PDF p. 1862026-03-12 | |
| SIMON HOO KIA WEI | 83,514,222 shares; 1.94%. | PDF p. 1862026-03-12 | |
| CHEN JOHNSON | 80,795,161 shares; 1.88%. | PDF p. 1862026-03-12 | |
| OCBC SECURITIES PRIVATE LTD | 78,598,150 shares; 1.83%. | PDF p. 1862026-03-12 | |
| TAY KUAN HUAT | 64,516,129 shares; 1.50%. | PDF p. 1862026-03-12 | |
| TAN WEIREN VINCENT (CHEN WEIREN VINCENT) | 60,000,000 shares; 1.40%. | PDF p. 1862026-03-12 | |
| ASDEW ACQUISITIONS PTE LTD | 55,000,000 shares; 1.28%. | PDF p. 1862026-03-12 | |
| LEONG HEE KUAN | 52,609,896 shares; 1.22%. | PDF p. 1862026-03-12 | |
| MOOMOO FINANCIAL SINGAPORE PTE. LTD. | 46,286,900 shares; 1.08%. | PDF p. 1862026-03-12 | |
| TAN KONG LUEN | 44,000,000 shares; 1.02%. | PDF p. 1862026-03-12 | |
Group structure
The table has30holding-path rows covering28distinct legal entities. RedDotHealthTechnology appears under its current and former parent after a transfer; PT Clearbridge Health Indonesia has separate5%and95%holding paths.
Both immediate-parent and effective Group ownership percentages for2025and2024 are disclosed. Two entities were struck off, and three were incorporated during2025. Dates, activities, countries and auditor footnotes are retained.
Clearbridge Australia’s Group ownership is printed as100%for2025and80.20%for2024. Clearbridge Distribution and LKDS(Simei) have Group interests of80.20%and40.90%respectively in both years.
| Company | Market | Ownership interest |
|---|---|---|
| Clearbridge BSA Pte. Ltd.Subsidiary holding path; held by CompanyPDF p. 141 | Country: Singapore; activities: Investment holding; parent2025: 100%; parent2024: 100%; Group2025: 100%; Group2024: 100% | |
| Clearbridge Assays Pte. Ltd.Subsidiary holding path; held by CompanyPDF p. 141 | Country: Singapore; activities: Investment holding; parent2025: 100%; parent2024: 100%; Group2025: 100%; Group2024: 100% | |
| Clearbridge Medical Group Pte. Ltd.Subsidiary holding path; held by CompanyPDF p. 141 | Country: Singapore; activities: Clinics/centres and other general medicine services; parent2025: 80.20%; parent2024: 80.20%; Group2025: 80.20%; Group2024: 80.20% | |
| CellTrust Bio Singapore Pte. Ltd.Subsidiary holding path; held by CompanyPDF p. 142 | Country: Singapore; activities: Investment holding; parent2025: 100%; parent2024: –%; Group2025: 100%; Group2024: –% | |
| Clearbridge Medical Hong Kong Corporation LimitedSubsidiary holding path; held by Clearbridge Medical Group Pte. Ltd.PDF p. 142 | Country: Hong Kong; activities: Biotechnology and life sciences; parent2025: 100%; parent2024: 100%; Group2025: 80.20%; Group2024: 80.20% | |
| Clearbridge Health (Philippines) Inc.Subsidiary holding path; held by Clearbridge Medical Group Pte. Ltd.PDF p. 142 | Country: Philippines; activities: Clinics/centres and other general medical services; parent2025: 99.99%; parent2024: 99.99%; Group2025: 80.19%; Group2024: 80.19% | |
| Clearbridge Medica Sdn. Bhd.Subsidiary holding path; held by Clearbridge Medical Group Pte. Ltd.PDF p. 142 | Country: Singapore; activities: Clinics/centres and other general medical services; parent2025: –%; parent2024: 100%; Group2025: –%; Group2024: 80.20% | |
| Clearbridge Lifestyle Pte. Ltd.Subsidiary holding path; held by Clearbridge Medical Group Pte. Ltd.PDF p. 142 | Country: Singapore; activities: Management consultancy for healthcare organisation; parent2025: 100%; parent2024: 100%; Group2025: 80.20%; Group2024: 80.20% | |
| Clearbridge Distribution Pte. Ltd.Subsidiary holding path; held by Clearbridge Medical Group Pte. Ltd.PDF p. 142 | Country: Singapore; activities: Wholesale of medicinal and pharmaceutical products; parent2025: 100%; parent2024: 100%; Group2025: 80.20%; Group2024: 80.20% | |
| Clearbridge Australia Pty. Ltd.Subsidiary holding path; held by Clearbridge Medical Group Pte. Ltd.PDF p. 142 | Country: Australia; activities: Dormant; parent2025: 100%; parent2024: 100%; Group2025: 100%; Group2024: 80.20% | |
| Clearbridge Medical Philippines, Inc.Subsidiary holding path; held by Clearbridge Health (Philippines) Inc.PDF p. 143 | Country: Philippines; activities: Clinics/centres and other general medical services; parent2025: 65%; parent2024: 65%; Group2025: 52.13%; Group2024: 52.13% | |
| RedDot Holding Co. Limited.Subsidiary holding path; held by CellTrust Bio Singapore Pte. Ltd.PDF p. 143 | Country: Hong Kong; activities: Provision of marketing services; parent2025: 100%; parent2024: –%; Group2025: 100%; Group2024: –% | |
| Cell Entrust Bio Co. LimitedSubsidiary holding path; held by CellTrust Bio Singapore Pte. Ltd.PDF p. 143 | Country: Hong Kong; activities: Cryopreservation biotechnology; parent2025: 100%; parent2024: –%; Group2025: 100%; Group2024: –% | |
| Shanghai Kai Zhun Health Management Co. Ltd.Subsidiary holding path; held by Clearbridge Medical Hong Kong Corporation LimitedPDF p. 143 | Country: China; activities: Distribution of medical devices and related services; parent2025: 100%; parent2024: 100%; Group2025: 80.20%; Group2024: 80.20% | |
| Red Dot Health Technology (Shanghai) Co. Ltd.Subsidiary holding path; held by Clearbridge Medical Hong Kong Corporation LimitedPDF p. 143 | Country: China; activities: Distribution of medical and lifestyle products; parent2025: 100%; parent2024: –%; Group2025: 80.20%; Group2024: 80.20% | |
| Clearbridge Dental Holdings Pte. Ltd.Subsidiary holding path; held by Clearbridge Lifestyle Pte. Ltd.PDF p. 143 | Country: Singapore; activities: Investment holding; parent2025: 51%; parent2024: 51%; Group2025: 40.90%; Group2024: 40.90% | |
| Red Dot Health Technology (Shanghai) Co. Ltd.Subsidiary holding path; held by Shanghai Kai Zhun Health Management Co. Ltd.PDF p. 143 | Country: China; activities: Distribution of medical and lifestyle products; parent2025: –%; parent2024: 100%; Group2025: 80.20%; Group2024: 80.20% | |
| Renum Distribution Holdings Pte. Ltd.Subsidiary holding path; held by Clearbridge Assays Pte. Ltd.PDF p. 144 | Country: Singapore; activities: Wholesale of medicinal and pharmaceutical products; parent2025: 100%; parent2024: 100%; Group2025: 100%; Group2024: 100% | |
| PT Clearbridge Health IndonesiaSubsidiary holding path; held by Clearbridge Assays Pte. Ltd.PDF p. 144 | Country: Indonesia; activities: Dormant; parent2025: 5%; parent2024: 5%; Group2025: 5%; Group2024: 5% | |
| PT Clearbridge Health IndonesiaSubsidiary holding path; held by Renum Distribution Holdings Pte. Ltd.PDF p. 144 | Country: Indonesia; activities: Dormant; parent2025: 95%; parent2024: 95%; Group2025: 95%; Group2024: 95% | |
| PT Clearbridge Medical IndonesiaSubsidiary holding path; held by PT Clearbridge Health IndonesiaPDF p. 144 | Country: Indonesia; activities: Dormant; parent2025: –%; parent2024: 49%; Group2025: –%; Group2024: 49% | |
| Dental Town (AMK) Pte. Ltd.Subsidiary holding path; held by Clearbridge Dental Holdings Pte. Ltd.PDF p. 144 | Country: Singapore; activities: Provision of dental and ancillary services; parent2025: 100%; parent2024: 100%; Group2025: 40.90%; Group2024: 40.90% | |
| LKDS (Hougang Green) Pte. Ltd.Subsidiary holding path; held by Clearbridge Dental Holdings Pte. Ltd.PDF p. 144 | Country: Singapore; activities: Provision of dental and ancillary services; parent2025: 100%; parent2024: 100%; Group2025: 40.90%; Group2024: 40.90% | |
| LKDS (Simei) Pte. Ltd.Subsidiary holding path; held by Clearbridge Dental Holdings Pte. Ltd.PDF p. 144 | Country: Singapore; activities: Provision of dental and ancillary services; parent2025: 100%; parent2024: 100%; Group2025: 40.90%; Group2024: 40.90% | |
| LKDS (Yishun) Pte. Ltd.Subsidiary holding path; held by Clearbridge Dental Holdings Pte. Ltd.PDF p. 144 | Country: Singapore; activities: Provision of dental and ancillary services; parent2025: 100%; parent2024: 100%; Group2025: 40.90%; Group2024: 40.90% | |
| Urban Dental (SG) Pte. Ltd.Subsidiary holding path; held by Clearbridge Dental Holdings Pte. Ltd.PDF p. 144 | Country: Singapore; activities: Provision of dental and ancillary services; parent2025: 100%; parent2024: 100%; Group2025: 40.90%; Group2024: 40.90% | |
| Dental Focus (Bendemeer) Pte. Ltd.Subsidiary holding path; held by Clearbridge Dental Holdings Pte. Ltd.PDF p. 145 | Country: Singapore; activities: Provision of dental and ancillary services; parent2025: 100%; parent2024: 100%; Group2025: 40.90%; Group2024: 40.90% | |
| Dental Focus (Pioneer) Pte. Ltd.Subsidiary holding path; held by Clearbridge Dental Holdings Pte. Ltd.PDF p. 145 | Country: Singapore; activities: Provision of dental and ancillary services; parent2025: 100%; parent2024: 100%; Group2025: 40.90%; Group2024: 40.90% | |
| Dentalfamily (Pioneer) Pte. Ltd.Subsidiary holding path; held by Clearbridge Dental Holdings Pte. Ltd.PDF p. 145 | Country: Singapore; activities: Provision of dental and ancillary services; parent2025: 100%; parent2024: 100%; Group2025: 40.90%; Group2024: 40.90% | |
| Dental Focus (People’s Park) Pte. Ltd.Subsidiary holding path; held by Clearbridge Dental Holdings Pte. Ltd.PDF p. 145 | Country: Singapore; activities: Provision of dental and ancillary services; parent2025: 100%; parent2024: 100%; Group2025: 40.90%; Group2024: 40.90% | |
Ownership interests and geographic information follow the annual report. Comparative years and footnote markers retain the report’s notation.
Senior executives
| Item | Value | Period / scope | Source |
|---|---|---|---|
| SIMON HOO KIA WEI | Chief Business Officer | PDF p. 16 | |
| TAN WEI CHEE | Financial Controller | PDF p. 16 | |
| Lin Moi Heyang | Company Secretary | As at 8 April 2026 | PDF p. 191 |
Extracted from ANNUAL REPORT 2025 and checked against the cited pages; see the original report for full context.
Related parties, people & properties
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Interested Person Transactions (“IPTs”) | There were no disclosable IPTs during FY2025. | Group, FY2025 | PDF p. 83 |
| Compensation of directors and key management personnel | 1,089 S$'000 | Group, 2025 (2024: 1,155 re-presented) | PDF p. 164 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Yee Pinh Jeremy | 530 S$'000 | FY2025, Total (S$'000) | PDF p. 70 |
| Chen Johnson | 60 S$'000 | FY2025, Total (S$'000) | PDF p. 70 |
| Andrew John Lord | 30 S$'000 | FY2025, Total (S$'000) | PDF p. 70 |
| Mark Benedict Ryan | 30 S$'000 | FY2025, Total (S$'000) | PDF p. 70 |
| Mah How Soon (Ma Haoshun) | 30 S$'000 | FY2025, Total (S$'000) | PDF p. 70 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Cessation of CEO | On 3 April 2026, Mr Yee Pinh Jeremy ceased to be the CEO of the Company and has been redesignated as Non-Executive Non-Independent Director of the Company. | Company · As at 2026-04-03 | PDF p. 70 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Letter from the Board - pull quote | We will continue to proactively evaluate our options and opportunities to preserve value for the Group and if need be, undertake certain corporate exercises to restructure our businesses and operations to achieve sustainability and to better position the Group for the future. | Group | PDF p. 8 |
Extracted from ANNUAL REPORT 2025 and checked against the cited pages; see the original report for full context.
Corporate information